Information updates

Updated ASCIA Action Plans

Following an extensive review process by the ASCIA anaphylaxis committee, ASCIA Action Plans have been updated.  The 2021 versions of the following plans are now available at

  • ASCIA Action Plan for Anaphylaxis (RED) EpiPen®, Anapen® and General with QR Code versions for adults or children with medically confirmed allergies, who have been prescribed adrenaline autoinjectors. Anapen® is expected to be available in Australia on the PBS from September 2021. 
  • ASCIA Action Plan for Drug (Medication) Allergy (GREEN) for adults or children with medically confirmed drug (medication) allergies, who have not been prescribed adrenaline autoinjectors.
  • ASCIA Action Plan for Allergic Reactions (GREEN) for adults or children with medically confirmed food or insect allergies, who have not been prescribed adrenaline autoinjectors. 

ASCIA Action Plans and First Aid Plans 2021The main change to the 2021 ASCIA Action Plans is that the number of positioning images has increased from three to five:

  • Each plan now includes images that show the recovery position and holding a young child flat, not upright.
  • Wording above the images has been expanded to provide more detailed explanations.

Other changes that have been made in response to requests by several reviewers are as follows:

  • The wording ‘- these are signs of anaphylaxis for insect allergy’ after ‘Abdominal pain, vomiting’ has been highlighted in bold.
  • ‘Give other medications (if prescribed)’ has been changed to ‘Give antihistamine (if prescribed)’.
  • In the left column the space for ‘Confirmed allergens’ has been expanded, wording has been updated in the family/emergency contacts, authorisation/consent and review sections, and the adrenaline doses have been reordered to start with the lowest dose of 150mg.

Current ASCIA Action Plans are the 2021 versions, however, the 2020 and 2018 versions are still valid for use throughout 2021. ASCIA Action Plans do not expire, and therefore the plan is still valid beyond the recommended review date, which is a guide for patients to see their doctor.

ASCIA First Aid Plans for Anaphylaxis (ORANGE) EpiPen®, Anapen® and General with QR Code versions have been updated to be consistent with the 2021 ASCIA Action Plans and are also available at


Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia